Cipla Limited — Q1FY27 earnings call summary

Filed 27 July 2026 · Official transcript

U.S. pipeline includes 3 respiratory and 1 peptide launch; $1B exit revenue target maintained
Multiple analyst queries on U.S. launches and margin trajectory; mgmt expects margin improvement with new products
Q1 FY27 revenue INR 7,119 Cr, +2% y-y (adjusted ~4% growth)
North America revenue $162M; Ventolin generic launched, ramp expected by FY end
Gross margin 62.5%, impacted by product mix, war costs, inventory charges
EBITDA margin 16.7% excluding other income; PAT INR 789 Cr (11% of sales)
One India business grew 12% y-y; branded prescription up 15.4%
R&D spend INR 486 Cr (6.8% of revenue); net cash INR 9,494 Cr post dividend